Mesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%

MT Newswires Live

Jul 18, 2025

Mesoblast (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.

The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.

The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.

The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.

Mesoblast's shares soared 25% in early trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2552300024"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552300024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552300024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552300024","market":"hk","top_or_hot":-1,"title":"Mesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MESO\">Mesoblast</a> (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.</p><p>The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.</p><p>The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.</p><p>The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.</p><p>Mesoblast's shares soared 25% in early trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Reports Over $13 Million in Gross Revenue From Ryoncil Product Sales; Shares Soar 25%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-18 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MESO\">Mesoblast</a> (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.</p><p>The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.</p><p>The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.</p><p>The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.</p><p>Mesoblast's shares soared 25% in early trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2552300024","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552300024","pubTimestamp":1752801415,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.Mesoblast's shares soared 25% in early trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD","MESO":"Mesoblast Limited"},"translate_title":"Mesoblast报告Ryoncil产品销售总收入超过1300万美元；股价飙升25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1,"MSB.AU":0.9},"content_text":"Mesoblast (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.Mesoblast's shares soared 25% in early trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}